Pharmacodynamic monitoring of BAY 43-9006 (sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells

Cytometry Part B - Clinical Cytometry

Volumn 70, Issue 3, 2006, Pages 107-114

  Tong, Frances K ^a   Chow, Sue ^a   Hedley, David ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

c kit; Pharmacodynamics; Signal transduction; Stem cell factor

Indexed keywords

CD34 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD34 SELECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE ACTIVATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, CD3; ANTIGENS, CD34; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BENZENESULFONATES; DRUG MONITORING; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HEMOLYSIS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTES, MONONUCLEAR; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; PHOSPHORYLATION; PYRIDINES; STEM CELL FACTOR; STEM CELLS; TETRADECANOYLPHORBOL ACETATE;

EID: 33646468642     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20092     Document Type: Article

References (20)

1. Dai Z, Huang Y, Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 2004;4:1347-1356.
2. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. P13K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
3. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer-implications for therapy. Semin Oncol 2004;31:90-119.
4. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189-218.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
6. Martin GS. Cell signaling and cancer. Cancer Cell 2003;4:167-174.
7. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003;22:395-403.
8. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-965.
9. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-947.
10. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
11. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-225.
12. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
13. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001;46:72-78.
14. Hotte SJ, Hirte HW. BAY 43-9006: Early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8:2249-2253.
15. Lee JT, Jr., McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002;16:486-507.
16. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 2005;67:4-17.
17. Hilger RA, Kredke S, Hedley D, Moeller JG, Bauer RJ, Stellberg W, Seeber S, Scheulen ME, Strumberg D. ERK1/2 phosphorylation: A biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther 2002;40:567-568.
18. Dutton DR, Bowden GT. Indirect induction of a clastogenic effect in epidermal cells by a tumor promoter. Carcinogenesis 1985;6:1279-1284.
19. Liaw YS, Yang PC, Yu CJ, Kuo SH, Luh KT, Lin YJ, Wu ML. PKC activation is required by EGF-stimulated Na(+)-H+ exchanger in human pleural mesothelial cells. Am J Physiol 1998;274:L665-L672.
20. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.